Opportunity Information: Apply for RFA HL 18 002
Apply for RFA HL 18 002
- The Department of Health and Human Services, National Institutes of Health in the health sector is offering a public funding opportunity titled "Perinatal Stroke (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839.
- This funding opportunity was created on Sep 23, 2016.
- Applicants must submit their applications by Feb 07, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $324,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Perinatal Stroke (R01) funding opportunity (RFA HL 18 002) is a discretionary NIH research grant issued by the U.S. Department of Health and Human Services through the National Institutes of Health. It is designed to expand the scientific and translational evidence base around perinatal stroke, with a clear emphasis on understanding disease mechanisms in the developing brain and moving toward intervention-relevant discoveries. The central goal is to stimulate research that can reveal actionable therapeutic targets, meaning the work is expected to illuminate biological pathways or modifiable processes that could ultimately support prevention, improved diagnosis, or treatment strategies tailored to newborns and very young infants affected by stroke.
This FOA specifically calls for basic and/or translational studies focused on the developing neurovascular unit and the biological response to perinatal stroke injury and repair. In practical terms, the neurovascular unit includes the coordinated system of brain blood vessels, endothelial cells, pericytes, astrocytes, neurons, extracellular matrix, and supporting signaling networks that together regulate blood flow, blood-brain barrier properties, and inflammatory responses. Because the perinatal brain is still developing, its vascular biology, barrier function, and immune environment differ in important ways from those of older children and adults. The opportunity therefore targets research that explains how these developmental differences shape stroke susceptibility, injury evolution, and recovery, and how those differences can be leveraged to design therapies that are developmentally appropriate rather than simply adapted from adult stroke paradigms.
A notable priority area in this announcement is research that examines vascular, hemostatic, hematopoietic, and immune cell activities in the developing brain. This emphasis highlights NIH interest in the interplay among blood vessel function, coagulation and clotting pathways, blood and immune cell development, and inflammatory or immune-mediated mechanisms that may contribute to stroke onset, progression, or outcomes in the perinatal period. Responsive applications might investigate, for example, how clot formation and breakdown are regulated in neonates, how platelet and coagulation factor dynamics differ from adults, how immune cell trafficking and activation affect brain injury or repair, or how developmental hematopoiesis and immune maturation influence vulnerability to ischemic or hemorrhagic events. Work that clarifies etiologies and risk factors is also encouraged, including studies that identify biological, genetic, maternal, placental, or perinatal contributors that increase stroke risk or shape severity and recovery trajectories.
The award mechanism is the R01, which generally supports hypothesis-driven projects with a defined research plan and measurable aims, suitable for well-scoped basic or translational programs. The opportunity lists an award ceiling of $324,000 and anticipates making approximately six awards, indicating a competitive program with limited slots. The original posting information shows a creation date of September 23, 2016 and an original closing date of February 7, 2017, which situates it as a specific, time-bounded solicitation rather than an open-ended standing program announcement.
Eligibility is broad and includes many organization types that commonly participate in NIH research, spanning public and private institutions of higher education, state and local governments, independent school districts, special district governments, federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories), for-profit organizations other than small businesses, and small businesses. This wide eligibility range signals an intent to attract multidisciplinary teams and diverse institutional capabilities, from academic medical centers and research universities to hospitals, research institutes, and other entities positioned to perform mechanistic studies, preclinical translational research, and potentially clinically relevant investigations aligned with the FOA scope.
Overall, this opportunity is best understood as a targeted NIH effort to catalyze deeper mechanistic understanding of perinatal stroke in the context of brain development, with particular attention to the neurovascular and blood-immune interfaces. The NIH focus on identifying therapeutic targets makes it clear that applications should not only describe perinatal stroke biology, but should also aim to generate insights that can plausibly inform intervention development, such as pinpointing pathways that can be modulated, identifying biomarkers linked to actionable mechanisms, or defining windows of vulnerability and repair that could guide timing and selection of future therapies.
Frequently Asked Questions (FAQs): Perinatal Stroke (R01) - RFA HL 18 002
What is the Perinatal Stroke (R01) funding opportunity (RFA HL 18 002)?
This is a discretionary NIH research grant opportunity issued by the U.S. Department of Health and Human Services through the National Institutes of Health. It uses the R01 mechanism and is intended to expand the scientific and translational evidence base around perinatal stroke.
What is the main goal of this funding opportunity?
The central goal is to stimulate research that improves understanding of disease mechanisms in the developing brain and moves toward intervention-relevant discoveries. The work is expected to reveal actionable therapeutic targets that could eventually support prevention, improved diagnosis, or treatment strategies for newborns and very young infants affected by stroke.
What types of studies does the FOA call for?
The FOA specifically calls for basic and/or translational studies focused on the developing neurovascular unit and the biological response to perinatal stroke injury and repair.
What is meant by the "developing neurovascular unit" in this announcement?
In practical terms, the neurovascular unit refers to the coordinated system of brain blood vessels, endothelial cells, pericytes, astrocytes, neurons, extracellular matrix, and supporting signaling networks that together regulate blood flow, blood-brain barrier properties, and inflammatory responses.
Why does the FOA emphasize the developing brain rather than adapting adult stroke concepts?
Because the perinatal brain is still developing, its vascular biology, barrier function, and immune environment differ in important ways from those of older children and adults. The opportunity targets research that explains how these developmental differences shape stroke susceptibility, injury evolution, and recovery, and how they can be leveraged to design therapies that are developmentally appropriate rather than simply adapted from adult stroke paradigms.
What priority research area is highlighted in the announcement?
A notable priority area is research examining vascular, hemostatic, hematopoietic, and immune cell activities in the developing brain, with an emphasis on the interplay among blood vessel function, coagulation/clotting pathways, blood and immune cell development, and inflammatory or immune-mediated mechanisms that may contribute to stroke onset, progression, or outcomes in the perinatal period.
What kinds of research examples are considered responsive based on the description?
Responsive applications might investigate how clot formation and breakdown are regulated in neonates; how platelet and coagulation factor dynamics differ from adults; how immune cell trafficking and activation affect brain injury or repair; or how developmental hematopoiesis and immune maturation influence vulnerability to ischemic or hemorrhagic events.
Does the FOA encourage studies on etiologies and risk factors for perinatal stroke?
Yes. Work that clarifies etiologies and risk factors is encouraged, including studies identifying biological, genetic, maternal, placental, or perinatal contributors that increase stroke risk or shape severity and recovery trajectories.
What funding mechanism is used for this opportunity?
The award mechanism is the NIH R01, which generally supports hypothesis-driven projects with a defined research plan and measurable aims, suitable for well-scoped basic or translational programs.
What is the award ceiling listed for this opportunity?
The opportunity lists an award ceiling of $324,000.
How many awards does NIH anticipate making?
The FOA anticipates making approximately six awards, indicating a competitive program with limited slots.
When was this opportunity created and when did it originally close?
The original posting shows a creation date of September 23, 2016 and an original closing date of February 7, 2017, indicating it was a specific, time-bounded solicitation rather than an open-ended standing program announcement.
Who is eligible to apply based on the information provided?
Eligibility is broad and includes: public and private institutions of higher education; state and local governments; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; and small businesses.
Does the broad eligibility suggest any particular approach or team composition?
The wide eligibility range signals an intent to attract multidisciplinary teams and diverse institutional capabilities, including entities positioned to perform mechanistic studies, preclinical translational research, and potentially clinically relevant investigations aligned with the FOA scope.
What should applicants keep in mind about "actionable therapeutic targets"?
The NIH focus on identifying therapeutic targets suggests applications should not only describe perinatal stroke biology, but also aim to generate insights that can plausibly inform intervention development, such as pinpointing pathways that can be modulated, identifying biomarkers linked to actionable mechanisms, or defining windows of vulnerability and repair that could guide the timing and selection of future therapies.
Is this opportunity focused only on diagnosis or only on treatment?
No. The described goal is to support work that could ultimately inform prevention, improved diagnosis, or treatment strategies tailored to newborns and very young infants, with a strong emphasis on mechanistic and translational evidence that points toward intervention-relevant discoveries.
What biological interfaces are emphasized as especially important for perinatal stroke research in this FOA?
The opportunity is best understood as emphasizing neurovascular biology and the blood-immune interfaces in the context of brain development, including vascular function, blood-brain barrier properties, hemostasis/coagulation, hematopoiesis, immune activity, and inflammatory responses as they relate to injury and repair after perinatal stroke.
Browse more opportunities from the same category: Health
Next opportunity: Strengthening the Capacity of Faith-based organizations (FBOs) and Faith-Based Health Systems to Sustain the Role of FBOs in a Coordinated Response to HIV/AIDS
Previous opportunity: Understanding the Epidemiology of Syphilis in the United States
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 18 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 18 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening the Capacity of Faith-based organizations (FBOs) and Faith-Based Health Systems to Sustain the Role of FBOs in a Coordinated Response to HIV/AIDS Apply for CDC RFA GH15 153803CONT17 Funding Number: CDC RFA GH15 153803CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (U01) Apply for RFA AA 17 014 Funding Number: RFA AA 17 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $500,000 |
| Strengthening of the Quality and Scope of Undergraduate and Postgraduate Medical and Public Health Training Programs at the University of Zambia, School of Medicine in the Republic of Zambia under the U.S. Presidents Emergency Plan for AIDS Relief PE Apply for CDC RFA GH12 124104CONT17 Funding Number: CDC RFA GH12 124104CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Capacity Building through Training/Mentoring for Treatment, Care and Support including Preventing Mother-to-Child Transmission (PMTCT); TB/HIV; Health System Strengthening; and Voluntary Medical Male Circumcision in Zambia under the President’s Eme Apply for CDC RFA GH15 159703CONT17 Funding Number: CDC RFA GH15 159703CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Support for Community Vital Registration in the Republic of Zambia under PEPFAR Apply for CDC RFA GH13 134904CONT17 Funding Number: CDC RFA GH13 134904CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Enhanced Community HIV Link - Northern Apply for RFA 440 16 000002 Funding Number: RFA 440 16 000002 Agency: Agency for International Development, Thailand USAID-Bangkok Category: Health Funding Amount: $4,500,000 |
| Support the Ministry of Health (MOH) to Scale up and Improve HIV/AIDS Prevention, Care, and Treatment Services in the Kingdom of Lesotho under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 154703CONT17 Funding Number: CDC RFA GH15 154703CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Improving Implementation of Programs for Care & Treatment of HIV/AIDS in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 156103CONT17 Funding Number: CDC RFA GH15 156103CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Implementation of a Program to Build the Institutional Capacity to Develop Strategic Information Capability for Individuals and Organizations that will contribute to Enhanced Quality in Collection, Management, Analysis and Presentation of HIV/AIDS Apply for CDC RFA GH12 124305CONT17 Funding Number: CDC RFA GH12 124305CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Improving Implementation of Programs for Care & Treatment of HIV/AIDS in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 131604CONT17 Funding Number: CDC RFA GH13 131604CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Improving Implementation of Programs for Care & Treatment of HIV/AIDS in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 131704CONT17 Funding Number: CDC RFA GH13 131704CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Strengthening Blood Transfusion Services in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 155903CONT17 Funding Number: CDC RFA GH15 155903CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Improving Implementation of Programs for Care & Treatment of HIV/AIDS in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 156503CONT17 Funding Number: CDC RFA GH15 156503CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Technical Assistance to Provide High-Quality Voluntary Medical Male Circumcision (VMMC) Services for Apply for CDC RFA GH15 153703CONT17 Funding Number: CDC RFA GH15 153703CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Increasing Access to HIV Prevention, Care and Treatment Services for Key Populations in Mozambique under the President’s Emergency Plan for AIDS Relief Apply for CDC RFA GH15 156403CONT17 Funding Number: CDC RFA GH15 156403CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Strengthening the Delivery and Expanding Access to Quality Laboratory Services and Enhancing Healthcare Worker and Laboratory Safety in the Republic of South Africa under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 157503CONT17 Funding Number: CDC RFA GH15 157503CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| National Genetics Education and Family Support Center Apply for HRSA 17 083 Funding Number: HRSA 17 083 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Building Systems and Capacity within the Cambodian Ministry of Health to Prevent New HIV Infections and AIDS-Related Deaths in Cambodia through PEPFAR Support to the National Center for HIV/AIDS, Dermatology, and STDS (NCHADS) under the President’s Apply for CDC RFA GH13 130305CONT17 Funding Number: CDC RFA GH13 130305CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Strengthening Public Health and the Public Health Laboratory System of Cambodia under the President’s Emergency Plan for AIDS Relief Program under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 130505CONT17 Funding Number: CDC RFA GH13 130505CONT17 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| HIV Program Evaluation Implementation Support for Activities Implemented under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1778 Funding Number: CDC RFA GH17 1778 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 18 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.